<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468936</url>
  </required_header>
  <id_info>
    <org_study_id>BMB 06-006</org_study_id>
    <secondary_id>OCC 2006-104</secondary_id>
    <nct_id>NCT00468936</nct_id>
  </id_info>
  <brief_title>Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms</brief_title>
  <official_title>Open-Label, Randomized Study Comparing the Patient Reported Severity of GI Side Effects of MMF Versus EC-MPS in Maintenance Heart Transplant Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stable heart transplant patients on Mycophenolate Mofetil (MMF) will sign a screening consent
      form in order to be evaluated with the gastrointestinal symptom rating scale (GSRS)
      questionnaire. Those who score three or more on at least two questions are eligible for the
      study. Once they sign a study consent they are randomized to one of two arms. It is thought
      that the severity of GI side effects will be reduced over time in patients who are in the
      Myfortic arm versus the severity of GI side effects over time in patients who remain on MMF
      treatment. Patients are evaluated by GSRS, The Psychological Well-Being Schedule, and the
      IT01/02 Checklist for the evaluation of GI symptoms and followed for one year (visits 1
      month, 3 months, 6 months, 12 months).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in GSRS score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Transplant Patients</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual medications (Cellcept)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients taking Myfortic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>enteric coated Cellcept pills in applicable dose for patient</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable dose MMF for at least 4 weeks

          -  Over 18 years of age

          -  Heart transplant at least three months prior to study

        Exclusion Criteria:

          -  GI symptoms known not to be caused by MPA therapy

          -  Acute rejection episode in past 4 weeks

          -  History of malignancy since transplant

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Nadia S Giannetti</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Nadia S Giannetti</last_name>
    <phone>(514) 934 1934</phone>
    <phone_ext>36511</phone_ext>
    <email>nadia.giannetti@muhc.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Barber</last_name>
      <phone>514 934 1934</phone>
      <phone_ext>36764</phone_ext>
      <email>charlene.barber@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Nadia Giannetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Nadia Giannetti</name_title>
    <organization>McGill University Health Center</organization>
  </responsible_party>
  <keyword>anti-rejection</keyword>
  <keyword>GI side effects</keyword>
  <keyword>heart transplant patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

